CN105832956A - Traditional Chinese medicine composition for treating myocardial infarction - Google Patents
Traditional Chinese medicine composition for treating myocardial infarction Download PDFInfo
- Publication number
- CN105832956A CN105832956A CN201610320870.6A CN201610320870A CN105832956A CN 105832956 A CN105832956 A CN 105832956A CN 201610320870 A CN201610320870 A CN 201610320870A CN 105832956 A CN105832956 A CN 105832956A
- Authority
- CN
- China
- Prior art keywords
- parts
- ginsenoside
- chinese medicine
- medicine composition
- caulis spatholobi
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/10—Preparation or pretreatment of starting material
- A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Abstract
The invention discloses a traditional Chinese medicine composition for treating myocardial infarction, and belongs to the technical field of traditional Chinese medicine. The traditional Chinese medicine composition is prepared from caulis spatholobi, radix angelica sinensis, common yam rhizomes, ginsenoside Rb1, ginsenoside Rg1, ginsenoside Rd, ginsenoside Re, rhizoma coptidis and licorice roots. The traditional Chinese medicine composition has the effects of breaking stagnation and eliminating blood stasis, invigorating the spleen and replenishing qi and clearing heat and removing toxicity and has the advantages of being simple in preparation technology, good in treatment effect, low in side effect, convenient to take, easy to apply and popularize and the like.
Description
The application is that the application for a patent for invention that applicant Linyi Cao Zhimei Pharmaceutical Technology Co., Ltd proposes is (invention entitled: a kind of Chinese medicine composition is for preparing the purposes in treatment myocardial infarction medicine, Application No.: 2015106521134, filing date: on October 10th, 2015) divisional application.
Technical field
The present invention relates to a kind of Chinese medicine composition treating myocardial infarction, belong to technical field of Chinese medicines.
Background technology
Myocardial infarction is the disease of the part myocardial necrosis caused due to the lasting severe ischemic of cardiac muscle, multiple be born in the middle age after, have violent and lasting character to be similar to the symptoms such as anginal front chest pain, cardiopalmus, asthma, weak and faint pulse, blood pressure reduction during morbidity.Primary disease incidence rate has and increases trend year by year, and arteriosclerosis accounts for the 98% of Pathogenesis of Acute Myocardial Infarction rate, and patient more than 40 years old is in the majority and many with hypertension, nearly half intentionally angor medical history.
In terms for the treatment of, it is broadly divided into two classes: one is to take stopgap measures and effect a permanent cure, i.e. " symptomatic treatment in acute condition, radical treatment in chronic case "；Two is routine treatment and contrary treatment, i.e. " treating with drugs opposite to the nature of disease is called routine treatment, contrary treatment means that the remedy coincides with the pseudo-symptom of disease ", and routine treatment is that the one controlled against its syndrome character commonly uses therapeutic rules, and contrary treatment is a kind of Therapeutic Method be obedient to disease illusion and control.Now the traditional Chinese medical science thinks that the main pathogenesis of coronary heart disease myocardial infarction is deficiency in origin and excess in superficiality, and deficiency in origin is based on the deficiency of vital energy, the deficiency of YIN, and mark is real turbid common with the stagnation of QI, blood stasis, expectorant.It is theoretical that the ancient prescription traditional Chinese medical science proposes phlegm and blood stasis, it is believed that body fluid transporting mistake department, stops gathering and forms expectorant；Escape of blood from meridians, stays in arteries and veins outer or stagnant in arteries and veins, causes blood stasis expectorant to stop or expectorant is poly-hinders blood；Or the expectorant stasis of blood changes mutually, stagnant in passages through which vital energy circulates to expectorant stasis blocking eventually, phlegm and blood stasis and cause a disease；And myocardial infarction is divided into type of deficiency of both QI and YIN, deficiency of YANG QI weak type, the expectorant stasis of blood hand over three types such as resistance qi stagnation and blood stasis type, control respectively with supplementing QI and nourishing YIN, QI invigorating warming YANG, dissipating phlegm and removing blood stasis.
Chinese patent application 201410113088.8 discloses a kind of Chinese medicine composition treating myocardial infarction, it is prepared raw material and includes: Galla Chinensis, Flos Lonicerae, the Cortex Eucommiae, Radix Cirsii Japonici, Rhizoma Chuanxiong, Radix Rehmanniae, Periostracum Cicadae, Poria, the Radix Paeoniae Alba, Radix Codonopsis and Radix Glycyrrhizae, this Chinese medicine composition has good therapeutic effect in terms for the treatment of myocardial infarction, there is significant clinical generalization value, but be not the most notable in the effect of the aspect such as supplementing QI and nourishing YIN, blood circulation promoting and blood stasis dispelling.
Summary of the invention
The technical problem to be solved in the present invention is to provide a kind of Chinese medicine composition treating myocardial infarction, this Chinese medicine composition has effect of removing blood stasis, invigorating the spleen and replenishing QI and heat-clearing and toxic substances removing, also have that preparation technology is simple, the advantage such as good effect, side effect are low, taking convenience and application easy to spread, additionally, the present invention also provides for corresponding manufacturing process, and this pharmaceutical composition is facilitated easy-to-use preparation ensureing to make on the premise of curative effect.
Chinese medicine composition of the present invention includes the raw material of following parts by weight: Caulis Spatholobi 10-15 part, Radix Angelicae Sinensis 4-10 part, Rhizoma Dioscoreae 4-10 part, ginsenoside Rb1's 1-10 part, ginsenoside Rg1's 1-10 part, ginsenoside Rd's 1-5 part, ginsenoside Re's 1-5 part, Rhizoma Coptidis 3-10 part and Radix Glycyrrhizae 3-10 part.
Preferably, described Chinese medicine composition includes the raw material of following parts by weight: Caulis Spatholobi 10 parts, Radix Angelicae Sinensis 6 parts, Rhizoma Dioscoreae 10 parts, ginsenoside Rb1 5 parts, ginsenoside Rg1 3 parts, ginsenoside Rd 3 parts, ginsenoside Re 5 parts, Rhizoma Coptidis 6 parts and 10 parts of Radix Glycyrrhizae.
Preferably, described Chinese medicine composition includes the raw material of following parts by weight: Caulis Spatholobi 15 parts, Radix Angelicae Sinensis 10 parts, Rhizoma Dioscoreae 6 parts, ginsenoside Rb1 10 parts, ginsenoside Rg1 8 parts, ginsenoside Rd 1 part, ginsenoside Re 1 part, Rhizoma Coptidis 10 parts and 5 parts of Radix Glycyrrhizae.
Preferably, described Chinese medicine composition includes the raw material of following parts by weight: Caulis Spatholobi 12 parts, Radix Angelicae Sinensis 4 parts, Rhizoma Dioscoreae 4 parts, ginsenoside Rb1 8 parts, ginsenoside Rg1 10 parts, ginsenoside Rd 5 parts, ginsenoside Re 3 parts, Rhizoma Coptidis 3 parts and 8 parts of Radix Glycyrrhizae.
Preferably, described Chinese medicine composition is made into tablet, capsule, drop pill, granule or powder.
Accordingly, the preparation method of described Chinese medicine composition comprises the steps:
A) Caulis Spatholobi is weighed, pulverize, adding medical material weight 2-5 times amount volume fraction is the ethanol solution of 60-90%, add the cellulase of medical material weight 1%-2%, extract 1-3 hour at 38-45 DEG C, then 85-95 DEG C of reflux, extract, 1-2 hour, filter and retain Caulis Spatholobi filtering residue, obtaining Caulis Spatholobi extracting solution；
B) weighing Radix Angelicae Sinensis, Rhizoma Dioscoreae, Rhizoma Coptidis and Radix Glycyrrhizae, add described Caulis Spatholobi filtering residue, be ground into coarse powder, add the ethanol solution that volumetric concentration is 60%-90%, reflux, extract, 1-2 time according to 3-6 times of coarse powder gross weight, return time is 3-8 hour, filters, obtains filtrate；
C) described Caulis Spatholobi extracting solution and described filtrate are merged, add ginsenoside Rb1, ginsenoside Rg1, ginsenoside Rd, ginsenoside Re, mixing, reclaim ethanol, be evaporated to the extractum of relative density 1.20-1.35, be dried, it is ground into powder, obtains Chinese medicine composition.
The source of component used by the present invention, nature and flavor, return through and effect:
Caulis Spatholobi: for the dry rattan of leguminous plant spatholobus suberectus；Bitter in the mouth, sweet, warm in nature；Return liver, kidney channel；Enrich blood, invigorate blood circulation, dredging collateral.
Radix Angelicae Sinensis: for the dry root of umbelliferae angelica；Sweet in the mouth, pungent, warm in nature；Return liver, the heart, spleen channel；Replenishing and activating blood, menstruction regulating and pain relieving, loosening bowel to relieve constipation.
Rhizoma Dioscoreae: for the dry rhizome of Dioscoreaceae plant Rhizoma Dioscoreae；Sweet in the mouth, property is put down；Return spleen, lung, kidney channel；Spleen reinforcing nourishing the stomach, promote the production of body fluid lung benefiting, the kidney invigorating arresting seminal emission.
Rhizoma Coptidis: for the dry rhizome of ranunculaceae plant Rhizoma Coptidis；Bitter in the mouth, cold in nature；GUIXIN, spleen, stomach, liver, gallbladder, large intestine channel；Heat clearing and damp drying, eliminating fire and detoxication.
Ginsenoside Rb1: derive from the dry root of Araliaceae Radix Ginseng；The effects such as Radix Ginseng has strongly invigorating primordial QI, strengthening by means of tonics, Fructus Alpiniae Oxyphyllae of calming the nerves, and promotes the production of body fluid, and multiple arteries and veins is admittedly de-；Research shows, ginsenoside Rb1 has protective effect to rat acute injury of renal tubular, and can promote that rabbit cartilage cell is bred.
Ginsenoside Rg1: derive from the dry root of Araliaceae Radix Ginseng；Radix Ginseng, by increasing bone marrow DNA, RNA, protein and the synthesis of lipid, promotes medullary cell mitosis, has the function stimulating hemopoietic；Ginsenoside Rg1 has the function promoting hemopoietic, also has the function of vital energy benefiting and the kidney invigorating.
Ginsenoside Rd: derive from the dry root of Araliaceae Radix Ginseng；There is strongly invigorating primordial QI, effect of strengthening by means of tonics.
Ginsenoside Re: derive from the dry root of Araliaceae Radix Ginseng；Its molecular formula is C48H82O18, and molecular weight is 947.14, has effect of kidney tonifying and blood benefiting.
Radix Glycyrrhizae: for the dry root of glycyrrhizic legume, Glycyrrhiza inflata Bat. or Glycyrrhiza glabra L.；Sweet in the mouth, property is put down；GUIXIN, lung, spleen, stomach warp；Invigorating the spleen and replenishing QI, heat-clearing and toxic substances removing, expelling phlegm for arresting cough, relieving spasm to stop pain, coordinating the actions of various ingredients in a prescription.
Compared with prior art, there is advantages that
1, Chinese medicine composition of the present invention is compared with the common drug of existing treatment myocardial infarction, has more significant effect at aspects such as removing blood stasis, invigorating the spleen and replenishing QI and heat-clearing and toxic substances removing.
2, compared with the chemicals of Current therapeutic myocardial infarction, Chinese medicine composition of the present invention is that natural pure Chinese medicinal preparation, untoward reaction and side effect significantly reduce, and Chinese medicine composition effect of the present invention is comprehensive, medication effect more preferably, efficiently solves the morbidity root of myocardial infarction.
The advantages such as the Chinese medicine composition that 3, the present invention relates to also has that compatibility science, preparation technology be simple, good effect, side effect are low, taking convenience and application easy to spread.
Detailed description of the invention
It will be understood by those skilled in the art that technology disclosed in following example represents the technology playing good action in the practice of the invention that the inventors discovered that.But, disclosed specific embodiments can be made many changes, and still obtain same or analogous result, without departing from the spirit and scope of the present invention.
Embodiment
1
Chinese medicine composition of the present invention is prepared from by the raw material of following parts by weight: Caulis Spatholobi 10 parts, Radix Angelicae Sinensis 6 parts, Rhizoma Dioscoreae 10 parts, ginsenoside Rb1 5 parts, ginsenoside Rg1 3 parts, ginsenoside Rd 3 parts, ginsenoside Re 5 parts, Rhizoma Coptidis 6 parts and 10 parts of Radix Glycyrrhizae.
Preparation method: weigh Caulis Spatholobi, pulverizes, and adding medical material weight 3 times amount volume fraction is the ethanol solution of 75%, add the cellulase of medical material weight 1.5%, extract at 40 DEG C 2 hours, then 90 DEG C of reflux, extract, 2 hours, filter and retain Caulis Spatholobi filtering residue, obtaining Caulis Spatholobi extracting solution；Weighing Radix Angelicae Sinensis, Rhizoma Dioscoreae, Rhizoma Coptidis and Radix Glycyrrhizae, add described Caulis Spatholobi filtering residue, be ground into coarse powder, be the ethanol solution of 75% according to 5 times of addition volumetric concentrations of coarse powder gross weight, reflux, extract, 2 times, return time is 6h, filters, obtains filtrate；Described Caulis Spatholobi extracting solution and described filtrate are merged, adds ginsenoside Rb1, ginsenoside Rg1, ginsenoside Rd, ginsenoside Re, mixing, reclaim ethanol, be evaporated to the extractum of relative density 1.25, dry, pulverize into powder, obtain Chinese medicine composition.In Chinese medicine composition, add starch, water, syrup, Pulvis Talci, mix homogeneously, tabletting, obtain the tablet of the embodiment of the present invention 1 Chinese medicine composition.
Embodiment
2
Chinese medicine composition of the present invention is prepared from by the raw material of following parts by weight: Caulis Spatholobi 15 parts, Radix Angelicae Sinensis 10 parts, Rhizoma Dioscoreae 6 parts, ginsenoside Rb1 10 parts, ginsenoside Rg1 8 parts, ginsenoside Rd 1 part, ginsenoside Re 1 part, Rhizoma Coptidis 10 parts and 5 parts of Radix Glycyrrhizae.
Preparation method is with embodiment 1.
Embodiment
3
Chinese medicine composition of the present invention is prepared from by the raw material of following parts by weight: Caulis Spatholobi 12 parts, Radix Angelicae Sinensis 4 parts, Rhizoma Dioscoreae 4 parts, ginsenoside Rb1 8 parts, ginsenoside Rg1 10 parts, ginsenoside Rd 5 parts, ginsenoside Re 3 parts, Rhizoma Coptidis 3 parts and 8 parts of Radix Glycyrrhizae.
Preparation method: weigh Caulis Spatholobi, pulverizes, and adding medical material weight 5 times amount volume fraction is the ethanol solution of 75%, add the cellulase of medical material weight 1%, extract at 45 DEG C 2 hours, then 85 DEG C of reflux, extract, 2 hours, filter and retain Caulis Spatholobi filtering residue, obtaining Caulis Spatholobi extracting solution；Weighing Radix Angelicae Sinensis, Rhizoma Dioscoreae, Rhizoma Coptidis and Radix Glycyrrhizae, add described Caulis Spatholobi filtering residue, be ground into coarse powder, be the ethanol solution of 75% according to 4 times of addition volumetric concentrations of coarse powder gross weight, reflux, extract, 2 times, return time is 4h, filters, obtains filtrate；Described Caulis Spatholobi extracting solution and described filtrate are merged, adds ginsenoside Rb1, ginsenoside Rg1, ginsenoside Rd, ginsenoside Re, mixing, reclaim ethanol, be evaporated to the extractum of relative density 1.25, dry, pulverize into powder, obtain Chinese medicine composition.In Chinese medicine composition, add lactose, mixing, stir, cross No. six sieves, obtain the powder of the embodiment of the present invention 3 Chinese medicine composition.
The Chinese medicine composition that the present invention relates to impact on myocardial infarction model rat
1, rat model is set up:
Select body weight 0.2kg-0.3kg male SD rat, lumbar injection 30mg/kg anaesthetized with pentobarbital rat.Back of the body position is fixed, and inhales ball with more than half, and with ALC-V8 type animal respirator, tidal volume 10ml/kg, 40-50 time/min of respiratory frequency, respiratory quotient is 1:1.Chest unhairing, sterilization, along left mid-clavicular line longitudinally slit skin 20mm, in the 4th, 5 intercostal blunt separation muscle layer, strut Intercostal muscle with curved hemostat and pleura enters thoracic cavity, cut off pericardium, gently press breast corridor, right side with middle finger, thumb pressure xiphoid-process bottom, extrusion heart, with great cardiac vein for mark between left auricle and pulmonary conus, under left auricle root, 2-3mm 6-0 hurtless measure suture passes left anterior descending coronary artery, depth of needle about 0.5mm, ligatures ramus descendens anterior arteriae coronariae sinistrae.Heart is sent back in thoracic cavity, extrude thoracic cavity gently, get rid of thoracic cavity air, layer-by-layer suture thoracic incision, close breast.The prevention in three days of postoperative intramuscular injection penicillin is infected.If mice still has vital sign, then modeling success.
2, experimental technique:
Choose 60 SD rats, it is randomly divided into 6 groups, often group 10, it is respectively Normal group, model group, positive controls, low dose group, middle dosage group and high dose group, in addition to Normal group, other group rats are modeled hands art, after modeling successfully, the normal saline that Normal group is corresponding with model group gavage, positive controls gavage FUFANG DANSHEN PIAN, after FUFANG DANSHEN PIAN is smashed to pieces, dilute becomes pasty state to carry out gastric infusion, low dose group, middle dosage group and the high dose group Chinese medicine composition composition powders that gavage embodiment 3 prepares respectively, pasty state is become to carry out gastric infusion powder dilute, concrete dosage is as shown in table 1.After gastric infusion two weeks, by rat anesthesia, abdomen cardinal vein takes hematometry creatine phosphokinase (CPK), glutamic oxaloacetic transaminase, GOT (AST) and lactic acid dehydrogenase (LDH).
3, experimental result:
The impact on myocardial infarction model rat of table 1 Chinese medicine composition of the present invention
Note: compare with model group,*P ＜ 0.05,*P ＜ 0.01.
The creatine phosphokinase of myocardial infarction patient, glutamic oxaloacetic transaminase, GOT and lactic acid dehydrogenase all can significantly raise, this experiment is by the research creatine phosphokinase of myocardial infarction model rat, glutamic oxaloacetic transaminase, GOT and the situation of change of lactic acid dehydrogenase, it is known that whether this experiment Chinese medicine composition has effective therapeutical effect for myocardial infarction.Result shows, compared with model group, CK, AST, LDH of high, medium and low dosage group all significantly reduces (P ＜ 0.01), has extremely significantly difference；CK, AST, LDH of positive controls the most all significantly reduces (P ＜ 0.01) compared with model group, but effective not as high, medium and low dosage group of effect, but no difference of science of statistics.Visible, Chinese medicine composition of the present invention can effectively reduce CK, AST, LDH value of rat, has significant effect for treatment myocardial infarction.
Clinical observation on the therapeutic effect
1, case selection: in 300 example myocardial infarction clinical volunteers patients, male patient 150 example, female patient 150 example, age bracket is 40-60 year, all patients is respectively provided with typical myocardial infarction clinical symptoms, and no difference of science of statistics in sex, age, the course of disease.
2, diagnostic criteria:
(1) typical case's myocardial ischemia symptom (chest pain or discomfort uncomfortable in chest)；
(2) typical cardiac electrical figure change；
(3) Serum fibrosis markers raises.
3, efficacy assessment standard:
Cure: after drug administration, malaise symptoms is wholly absent；
Effective: after drug administration, malaise symptoms alleviates or partial disappearance；
Invalid: after drug administration, malaise symptoms is unchanged；
Total effective rate=(cure+effectively)/total number of cases × 100%.
4, instructions of taking: 300 patients are randomly divided into 3 groups, often organize 100 people, is respectively treatment A group, treatment B group and matched group, and treatment A group, treatment B component are not taken tablet and the powder that the embodiment of the present invention 1,3 prepares, serve on 1 month.Matched group takes FUFANG DANSHEN DIWAN (Tianjin Tasly Pharmaceutical Co., Ltd, traditional Chinese medicines quasi-word Z10950111), and oral or sublingual administration, 10 balls, 3 times on the one, 4 weeks be a course for the treatment of.
5, therapeutic outcome: as shown in table 2.
Table 2 therapeutic outcome
This test uses FUFANG DANSHEN DIWAN as a control group, by comparing with the therapeutic effect of Chinese medicine composition of the present invention, it can be seen that the curative effect in terms of traditional Chinese medicine composition for treating myocardial infarction of the present invention.The cure rate of Chinese medicine composition of the present invention and total effective rate all reach more than 85%, and higher than cure rate and the total effective rate of matched group, wherein the therapeutic effect with treatment B group is best.Visible, the good effect of Chinese medicine composition of the present invention, cure rate is high, can be as the drug use for the treatment of myocardial infarction.
Owing to describing the present invention by above preferred embodiment, in the spirit and/or scope of the present invention, the present invention is implemented in any replacement/for the present invention or combination, will be apparent from for a person skilled in the art, and is included among the present invention.
Claims (6)
1. the Chinese medicine composition treating myocardial infarction, it is characterised in that include the raw material of following parts by weight: Caulis Spatholobi 10-15 part, Radix Angelicae Sinensis 4-10 part, Rhizoma Dioscoreae 4-10 part, ginsenoside Rb1's 1-10 part, ginsenoside Rg1's 1-10 part, ginsenoside Rd's 1-5 part, ginsenoside Re's 1-5 part, Rhizoma Coptidis 3-10 part and Radix Glycyrrhizae 3-10 part.
2. the as claimed in claim 1 Chinese medicine composition treating myocardial infarction, it is characterised in that include the raw material of following parts by weight: Caulis Spatholobi 10 parts, Radix Angelicae Sinensis 6 parts, Rhizoma Dioscoreae 10 parts, ginsenoside Rb1 5 parts, ginsenoside Rg1 3 parts, ginsenoside Rd 3 parts, ginsenoside Re 5 parts, Rhizoma Coptidis 6 parts and 10 parts of Radix Glycyrrhizae.
3. the as claimed in claim 1 Chinese medicine composition treating myocardial infarction, it is characterised in that include the raw material of following parts by weight: Caulis Spatholobi 15 parts, Radix Angelicae Sinensis 10 parts, Rhizoma Dioscoreae 6 parts, ginsenoside Rb1 10 parts, ginsenoside Rg1 8 parts, ginsenoside Rd 1 part, ginsenoside Re 1 part, Rhizoma Coptidis 10 parts and 5 parts of Radix Glycyrrhizae.
4. the as claimed in claim 1 Chinese medicine composition treating myocardial infarction, it is characterised in that include the raw material of following parts by weight: Caulis Spatholobi 12 parts, Radix Angelicae Sinensis 4 parts, Rhizoma Dioscoreae 4 parts, ginsenoside Rb1 8 parts, ginsenoside Rg1 10 parts, ginsenoside Rd 5 parts, ginsenoside Re 3 parts, Rhizoma Coptidis 3 parts and 8 parts of Radix Glycyrrhizae.
5. the Chinese medicine composition of the treatment myocardial infarction as described in claim 1-4 is arbitrary, it is characterised in that: described Chinese medicine composition is made into tablet, capsule, drop pill, granule or powder.
6. the Chinese medicine composition of the treatment myocardial infarction as described in claim 1-4 is arbitrary, it is characterised in that described Chinese medicine composition comprises the following steps:
(1) Caulis Spatholobi is weighed, pulverize, adding medical material weight 2-5 times amount volume fraction is the ethanol solution of 60-90%, add the cellulase of medical material weight 1%-2%, extract 1-3 hour at 38-45 DEG C, then 85-95 DEG C of reflux, extract, 1-2 hour, filter and retain Caulis Spatholobi filtering residue, obtaining Caulis Spatholobi extracting solution；
(2) weigh Radix Angelicae Sinensis, Rhizoma Dioscoreae, Rhizoma Coptidis and Radix Glycyrrhizae, add described Caulis Spatholobi filtering residue, be ground into coarse powder, adding the ethanol solution that volumetric concentration is 60%-90%, reflux, extract, 1-2 time according to 3-6 times of coarse powder gross weight, return time is 3-8 hour, filter, obtain filtrate；
(3) described Caulis Spatholobi extracting solution and described filtrate are merged, add ginsenoside Rb1, ginsenoside Rg1, ginsenoside Rd, ginsenoside Re, mixing, reclaim ethanol, be evaporated to the extractum of relative density 1.20-1.35, be dried, it is ground into powder, obtains Chinese medicine composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610320870.6A CN105832956A (en) | 2015-10-10 | 2015-10-10 | Traditional Chinese medicine composition for treating myocardial infarction |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610320870.6A CN105832956A (en) | 2015-10-10 | 2015-10-10 | Traditional Chinese medicine composition for treating myocardial infarction |
| CN201510652113.4A CN105079397A (en) | 2015-10-10 | 2015-10-10 | Application of traditional Chinese medicine composition to preparation of drugs for treating myocardial infarction |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510652113.4A Division CN105079397A (en) | 2015-10-10 | 2015-10-10 | Application of traditional Chinese medicine composition to preparation of drugs for treating myocardial infarction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105832956A true CN105832956A (en) | 2016-08-10 |
Family
ID=54561322
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510652113.4A Withdrawn CN105079397A (en) | 2015-10-10 | 2015-10-10 | Application of traditional Chinese medicine composition to preparation of drugs for treating myocardial infarction |
| CN201610320870.6A Withdrawn CN105832956A (en) | 2015-10-10 | 2015-10-10 | Traditional Chinese medicine composition for treating myocardial infarction |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510652113.4A Withdrawn CN105079397A (en) | 2015-10-10 | 2015-10-10 | Application of traditional Chinese medicine composition to preparation of drugs for treating myocardial infarction |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN105079397A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104887747A (en) * | 2015-07-06 | 2015-09-09 | 苗怡文 | Traditional Chinese medicine composition for treating cerebral thrombosis and preparation method therefor |
| CN104940279A (en) * | 2015-07-27 | 2015-09-30 | 青岛蓝盛洋医药生物科技有限责任公司 | Application of Chinese herbal composition to preparation of medicine for treating myocardial infarction |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1806830A (en) * | 2005-01-18 | 2006-07-26 | 北京凯瑞创新医药科技有限公司 | Chinese medicinal composition, its preparation process and quality control method |
| CN1285358C (en) * | 2005-06-28 | 2006-11-22 | 青岛国风药业股份有限公司 | Medicinal composition, preparation and quality control thereof |
| CN103816280B (en) * | 2014-03-25 | 2015-05-13 | 崔新明 | Traditional Chinese medicine composition for treating myocardial infarction and application of traditional Chinese medicine composition |
| CN104547771A (en) * | 2014-12-31 | 2015-04-29 | 东莞市智健医疗科技有限公司 | Use of traditional Chinese medicine preparation in preparation of medicine for treating cerebral ischemia disease |
-
2015
- 2015-10-10 CN CN201510652113.4A patent/CN105079397A/en not_active Withdrawn
- 2015-10-10 CN CN201610320870.6A patent/CN105832956A/en not_active Withdrawn
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104887747A (en) * | 2015-07-06 | 2015-09-09 | 苗怡文 | Traditional Chinese medicine composition for treating cerebral thrombosis and preparation method therefor |
| CN104940279A (en) * | 2015-07-27 | 2015-09-30 | 青岛蓝盛洋医药生物科技有限责任公司 | Application of Chinese herbal composition to preparation of medicine for treating myocardial infarction |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105079397A (en) | 2015-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102772745B (en) | Chinese medicinal preparation for treating cancer and preparation method thereof | |
| CN102210820A (en) | Chinese medicinal composition for treating leukemia | |
| CN104922543A (en) | Medicine composite for treating amenorrhea and preparation method thereof | |
| CN103110762A (en) | Traditional Chinese medicine composition for treating old fracture | |
| CN103285343B (en) | Medicine for treating liver cancer and preparation method thereof | |
| CN105796685A (en) | Method for preparing traditional Chinese medicine composition for treating myocardial infarction | |
| CN105343761A (en) | Traditional Chinese medicine composition for treating myocardial infarction and preparation method thereof | |
| CN105456924A (en) | Traditional Chinese medicine preparation containing Folium Artemisiae Argyi and having functions of promoting circulation and removing stasis and preparation method thereof | |
| CN104873911A (en) | Traditional Chinese medicine for oral administration for adjunctively treating sepsis | |
| CN104940279A (en) | Application of Chinese herbal composition to preparation of medicine for treating myocardial infarction | |
| CN105311425A (en) | Application of pharmaceutical composition containing folium artemisiae argyi in preparing medicine for treating myocardial infarction | |
| CN104013842A (en) | A traditional Chinese medicine composition used for treating viral myocarditis | |
| CN105832956A (en) | Traditional Chinese medicine composition for treating myocardial infarction | |
| CN107213219A (en) | Treat the Chinese medicine preparation of cardiovascular and cerebrovascular disease | |
| CN108310207B (en) | Pharmaceutical composition for treating heart failure and preparation method thereof | |
| CN105213770A (en) | A kind of Chinese medicine composition is for the preparation of the purposes in treatment myocardial infarction medicine | |
| CN101224295A (en) | Chinese traditional medicine compounds for treating digestive system tumor and preparing method thereof | |
| CN105748735A (en) | Pharmaceutical composition for treating ovarian cyst and preparation method thereof | |
| CN105288037A (en) | Application of medicine composition for preparing medicine for treating myocardial infarction | |
| CN105213743A (en) | A kind of Chinese medicine composition is for the preparation of the purposes in treatment myocardial infarction medicine | |
| CN105343508A (en) | Method for preparing traditional Chinese medicine composition for treating climacteric syndrome | |
| CN104524535A (en) | Traditional Chinese medicine composition for treating chronic pulmonary heart disease and preparation method of traditional Chinese medicine composition | |
| CN105362610A (en) | Traditional Chinese medicine composition for treating coronary artery diseases | |
| CN104758888A (en) | Traditional Chinese medicine composition for treating diabetes | |
| CN104623061B (en) | A kind of antifatigue |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20160810 |
|
| WW01 | Invention patent application withdrawn after publication |